Entera Bio (ENTX) Total Current Liabilities (2017 - 2026)

Entera Bio has disclosed Total Current Liabilities across 9 years of filings, most recently posting $1.6 million for Q1 2026.

• Quarterly Total Current Liabilities fell 2.9% year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (down 2.9% YoY) and the FY2025 annual result came in at $2.2 million, up 87.33% from the prior year.
• Total Current Liabilities eased to $1.6 million in Q1 2026, from $2.2 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $2.3 million in Q1 2022 and troughed at $1.1 million in Q4 2023.
• A 5-year average of $1.6 million and a median of $1.6 million in 2025 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Current Liabilities sank 57.58% — and 2025, when it surged 87.33%.
• Tracing ENTX's Total Current Liabilities over 5 years: stood at $1.3 million in 2022, then decreased by 18.64% to $1.1 million in 2023, then increased by 7.79% to $1.2 million in 2024, then surged by 87.33% to $2.2 million in 2025, then retreated by 28.46% to $1.6 million in 2026.
• Business Quant data shows ENTX's Total Current Liabilities at $1.6 million in Q1 2026, $2.2 million in Q4 2025, and $1.6 million in Q3 2025.